Pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on Hepatitis C virologic response

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 5, 2014, Pages 599-608

  Nguyen, T H T ^a   Mentre F ^a   Levi, M ^b   Yu, J ^c   Guedj, J ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; PEGINTERFERON ALPHA2A; PLACEBO; VIRUS RNA; ANTIVIRUS AGENT; CYCLOSPORIN; INTERFERON;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MICHAELIS CONSTANT; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GENOTYPE; HEPACIVIRUS; MALE; VIROLOGY;

ANTIVIRAL AGENTS; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MODELS, BIOLOGICAL;

EID: 84908204672     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.173     Document Type: Article

References (49)

1. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342 (2013).
2. Flisiak, R., Jaroszewicz, J. & Parfieniuk-Kowerda, A. Emerging treatments for hepatitis C. Expert Opin. Emerg. Drugs 18, 461-475 (2013).
3. Gentile, I. et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of a new era. Rev. Recent Clin. Trials 9, 1-7 (2014).
4. Au, J. S. & Pockros, P. J. Novel therapeutic approaches for hepatitis C. Clin. Pharmacol. Ther. 95, 78-88 (2014).
5. Gallay, P. A. & Lin, K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des. Devel. Ther. 7, 105-115 (2013).
6. Flisiak, R., Jaroszewicz, J., Flisiak, I. & Lapinski, T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin. Investig. Drugs 21, 375-382 (2012).
7. Crabbe, R., Vuagniaux, G., Dumont, J. M., Nicolas-Metral, V., Marfurt, J. & Novaroli, L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin. Investig. Drugs 18, 211-220 (2009).
8. Garcia-Rivera, J. A. et al. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob. Agents Chemother. 56, 5113-5121 (2012).
9. Flisiak, R. et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49, 1460-1468 (2009).
10. Guedj, J., Rong, L., Dahari, H. & Perelson, A. S. A perspective on modelling hepatitis C virus infection. J. Viral Hepat. 17, 825-833 (2010).
11. Chatterjee, A., Smith, P. F. & Perelson, A. S. Hepatitis C viral kinetics: the past, present, and future. Clin. Liver Dis. 17, 13-26 (2013).
12. Chatterjee, A., Guedj, J. & Perelson, A. S. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir. Ther. (Lond. ) 17, 1171-1182 (2012).
13. Guedj, J. et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. U. S. A. 110, 3991-3996 (2013).
14. Guedj, J., Dahari, H., Pohl, R. T., Ferenci, P. & Perelson, A. S. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J. Hepatol. 56, 1019-1024 (2012).
15. Shudo, E., Ribeiro, R. M. & Perelson, A. S. Modeling HCV kinetics under therapy using PK and PD information. Expert Opin. Drug Metab. Toxicol. 5, 321-332 (2009).
16. Lindh, M. et al. Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin. J. Viral Hepat. 20, e82-e89 (2013).
17. Mihm, U., Herrmann, E., Sarrazin, C. & Zeuzem, S. Review article: predicting response in hepatitis C virus therapy. Aliment. Pharmacol. Ther. 23, 1043-1054 (2006).
18. Nguyen, T. H., Guedj, J., Yu, J., Levi, M. & Mentre, F. Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome. CPT. Pharmacometrics Syst. Pharmacol. 2, e56 (2013).
19. Sypsa, V. & Hatzakis, A. Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials. Stat. Med. 27, 6505-6521 (2008).
20. Laouenan, C. et al. Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virusinfected cirrhotic patients. Antimicrob. Agents Chemother. 58, 5332-5341 (2014).
21. Guedj, J. et al. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology 59, 1706-1714 (2014).
22. Flisiak, R. et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47, 817-826 (2008).
23. Lee, J. I., Zhang, L., Men, A. Y., Kenna, L. A. & Huang, S. M. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49, 295-310 (2010).
24. Aitken, A. E. & Morgan, E. T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos. 35, 1687-1693 (2007).
25. Islam, M. et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin. Cancer Res. 8, 2480-2487 (2002).
26. Flaman, A. S., Gravel, C., Hashem, A. M., Tocchi, M. & Li, X. The effect of interferon-a on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol. Appl. Pharmacol. 253, 130-136 (2011).
27. Chen, C., Han, Y. H., Yang, Z. & Rodrigues, A. D. Effect of interferon-a2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes. Xenobiotica. 41, 476-485 (2011).
28. Le Vee, M., Jouan, E., Moreau, A. & Fardel, O. Regulation of drug transporter mRNA expression by interferon- in primary human hepatocytes. Fundam. Clin. Pharmacol. 25, 99-103 (2011).
29. Fernandez, C., Buyse, M., German-Fattal, M. & Gimenez, F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci. 7, 359-371 (2004).
30. Weiss, J., Becker, J. P. & Haefeli, W. E. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro. Int. J. Antimicrob. Agents 43, 184-188 (2014).
31. Garg, V., Kauffman, R. S., Beaumont, M. & van Heeswijk, R. P. Telaprevir: pharmacokinetics and drug interactions. Antivir. Ther. (Lond. ) 17, 1211-1221 (2012).
32. Forestier, N. et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46, 640-648 (2007).
33. Bruno, R. et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir. Ther. (Lond. ) 9, 491-497 (2004).
34. Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539-551 (2001).
35. Dahari, H. et al. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J. Hepatol. 53, 460-467 (2010).
36. Zhang, L., Beal, S. L. & Sheiner, L. B. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J. Pharmacokinet. Pharmacodyn. 30, 387-404 (2003).
37. Comets, E., Brendel, K. & Mentre, F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput. Methods Programs Biomed. 90, 154-166 (2008).
38. Nguyen, T. H., Comets, E. & Mentre, F. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. J. Pharmacokinet. Pharmacodyn. 39, 499-518 (2012).
39. Mentre, F. & Escolano, S. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J. Pharmacokinet. Pharmacodyn. 33, 345-367 (2006).
40. Paeshuyse, J. et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761-770 (2006).
41. Neumann, A. U. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182, 28-35 (2000).
42. Medeiros-Filho, J. E. et al. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J. Gastroenterol. 12, 7271-7277 (2006).
43. Guedj, J., Bazzoli, C., Neumann, A. U. & Mentre, F. Design evaluation and optimization for models of hepatitis C viral dynamics. Stat. Med. 30, 1045-1056 (2011).
44. Rotman, Y. et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 63, 161-169 (2014).
45. Pawlotsky, J. M. et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 703-714 (2004).
46. Dixit, N. M., Layden-Almer, J. E., Layden, T. J. & Perelson, A. S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922-924 (2004).
47. Snoeck, E. et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharmacol. Ther. 87, 706-713 (2010).
48. Guedj, J., Dahari, H., Shudo, E., Smith, P. & Perelson, A. S. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55, 1030-1037 (2012).
49. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).